JAMES OROURKE: Open Payments
NPI 1811572910 · FRANKLIN, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,319 in 65 payments from 14 companies in 2025. Trend: 2023 $679 · 2024 $949 · 2025 $1,319
Food & beverage: $1,285Education: $34
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $244 |
| GlaxoSmithKline, LLC. | 18 | $223 |
| Amgen Inc. | 10 | $183 |
| Novartis Pharmaceuticals Corporation | 8 | $178 |
| CSL Behring | 7 | $155 |
| GENZYME CORPORATION | 3 | $71 |
| Genentech USA, Inc. | 2 | $56 |
| Regeneron Healthcare Solutions, Inc. | 2 | $45 |
| Azurity Pharmaceuticals, Inc. | 2 | $38 |
| Cycle Pharmaceuticals Inc | 1 | $32 |
Products named: NUCALA, FASENRA, TEZSPIRE, DUPIXENT, XOLAIR, Hizentra, AIRSUPRA, Andembry.
Industry payments across TN — which companies pay providers there.
